| Heading: |
Medical Treatments |
| Question ID: |
1807536 |
| UIN: |
55969 |
| House: |
Commons |
| Date tabled: |
2025-05-30 |
| Asking Member ID: |
5329 |
| Asking Member display name: |
John Milne
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
John Milne
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what discussions he has had with steps NICE on ensuring greater (a) clarity and (b) transparency in relation to how carer quality of life is considered within its medicines appraisal framework. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence’s (NICE) technology appraisal process allows its independent committees to take all health-related costs and benefits, including health-related quality-of-life for carers, and impacts on personal socia... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |